CN105884755A - Deuterium-modified carbon glycoside derivate - Google Patents
Deuterium-modified carbon glycoside derivate Download PDFInfo
- Publication number
- CN105884755A CN105884755A CN201610077280.5A CN201610077280A CN105884755A CN 105884755 A CN105884755 A CN 105884755A CN 201610077280 A CN201610077280 A CN 201610077280A CN 105884755 A CN105884755 A CN 105884755A
- Authority
- CN
- China
- Prior art keywords
- compound
- sugar
- 300mhz
- thiophene
- fluorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 Cc(c(C(*)(*)c1ccc(-c(cc2)ccc2F)[s]1)c1)ccc1Br Chemical compound Cc(c(C(*)(*)c1ccc(-c(cc2)ccc2F)[s]1)c1)ccc1Br 0.000 description 6
- DSNLQVKYUASMTN-UHFFFAOYSA-N Cc(c(C(c1ccc(-c(cc2)ccc2F)[s]1)=O)c1)ccc1Br Chemical compound Cc(c(C(c1ccc(-c(cc2)ccc2F)[s]1)=O)c1)ccc1Br DSNLQVKYUASMTN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of medinal chemistry and relates to a deuterium-modified carbon glycoside derivate, in particular to a compound shown in the formula I. The invention further relates to a preparation method of the deuterium-modified carbon glycoside derivate, a medicine composition comprising the deuterium-modified carbon glycoside derivate and application of the deuterium-modified carbon glycoside derivate or the medicine composition thereof for preparing medicine for treating diabetes.
Description
Technical field
The invention belongs to medicinal chemistry art, relate to the carbon glycoside derivative that deuterium is modified.The invention still further relates to its preparation method,
The pharmaceutical composition of the carbon glycoside derivative containing deuterated modification, the carbon glycoside derivative of deuterated modification and pharmaceutical composition thereof are controlled in preparation
Treat the purposes in the medicine of diabetes.
Background technology
SGLT2 is the novel targets of the treatment diabetes of discovered in recent years.Glucose in blood plasma is filtered in glomerulus,
And be actively absorbed from the gastrointestinal tract again at Renal proximal tubular and to return in blood, research shows, SGLT2 is control this heavy absorption process main
Albumen.Therefore, the activity of suppression SGLT2 just can increase the excretion of glucose in urine thus reduce blood sugar concentration.
Canagliflozin (canagliflozin, (1S)-1,5-dehydrogenation-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl] methyl]-4-
Aminomethyl phenyl]-D-Glucose alcohol) be current first acquisition FDA approval SGLT2 inhibitor class medicine.Canagliflozin leads to
Cross the suppression kidney heavily absorption to glucose, increase glucose excretion, and then reduce the blood sugar level that diabetic has raised.
At present, canagliflozin single therapy and (include melbine, sulfonylurea, Pioglitazone and pancreas with other antidiabetic drug
Island element) correlative study of drug combination is complete.Canagliflozin should not be used in type 1 diabetes patient, Diabetic ketosis
Acid poisoning patient, severe renal impairment, End-stage renal disease patient or dialysis patient.
FDA requires that canagliflozin studies after improving five listings: cardiovascular lapse to test, in terms of pharmacovigilance
Research (is strengthened malignant tumour, serious pancreatitis, severe allergic reaction, light sensitivity reaction, liver exception and Disadvantage pregnancy result
Monitoring), bone security study and two researchs for child patient (include pharmacokinetics, pharmacodynamic study and safety
Study on the efficiency).Side effect common for canagliflozin has Vaginal Fungi to infect (vulvovaginal candidiasis) and urinary tract sense
Dye.Owing to canagliflozin is relevant to diuresis, so this medicine can cause blood volume to reduce, so cause orthostatic or
Postural hypotension (when standing, blood pressure reduces suddenly), or therefore cause dizziness or faintness symptom.These symptoms are at treatment head
Three months more typically.Although canagliflozin clinical efficacy is notable, but when continuing to need few side effects and effect clinically
Between long highly effective and safe antidiabetic drug.
Summary of the invention
One aspect of the present invention offer compound shown in a kind of Formulas I or its pharmaceutically acceptable salt:
Wherein R1、R2Independently selected from H (hydrogen), D (deuterium) or OH;R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15
Separately selected from H (hydrogen) or D (deuterium), R3Independently selected from C1-C4Alkyl or deuterated C1-C4Alkyl, condition is R1~R15In
Including at least a D-atom.
In the certain preferred embodiments of the present invention, R3Independently selected from CH3、CH2D、CHD2Or CD3。
In the certain preferred embodiments of the present invention, the example of compound shown in Formulas I is as follows:
In the embodiment of present invention further optimization, the example of the compound shown in Formulas I is as follows:
Term " pharmaceutically acceptable salt " refers to remain the biological efficacy of the free bronsted lowry acids and bases bronsted lowry of specific compound and do not have
There is the salt of biology ill-effect.The example of pharmaceutically acceptable salt includes but not limited to: (1) acid-addition salts, and inorganic acid
The salt that such as hydrochloric acid, sulfuric acid, hydrobromic acid, nitric acid, phosphoric acid etc. are formed;Or and organic acids such as malic acid, fumaric acid, maleic acid,
Benzoic acid, phenylacetic acid, butanedioic acid, tartaric acid, citric acid, methanesulfonic acid, ethyl sulfonic acid, hydroxyacetic acid, cinnamic acid, pyruvic acid, formic acid,
The salt that acetic acid, propionic acid, oxalic acid, malonic acid, acrylic acid, mandelic acid etc. are formed;Or (2) base addition salts, and alkali metal such as lithium,
The salt that sodium, potassium etc. are formed;The salt formed with alkaline-earth metal such as calcium, magnesium etc.;With organic bases such as ammonium, choline, diethanol amine, rely
Propylhomoserin, ethylenediamine, tert-butylamine, t-octanylamine, three (methylol) aminomethane, N-methyl glucose osamine, triethanolamine, dehydrogenated rosin
The salt that amine etc. are formed.
If any atom of the compound of institute's labelled synthesis does not specify in the present invention, any of this atom can be represented
A kind of stable isotope.Unless stated otherwise, when position a certain in structure is defined as H i.e. hydrogen (H-1), this position only contains
Naturally occurring isotopic mass.Equally, unless stated otherwise, when position a certain in structure is defined as D i.e. deuterium (H-2), should
Position containing at least big than naturally occurring isotopic mass (0.015%) 3340 times of isotopic mass (i.e. to I haven't seen you for ages 50.1% deuterium coordination
Element).
In the present invention, the deuterated rate of the compound of institute's labelled synthesis refers to the isotopic content of labelled synthesis and naturally occurs
The ratio of isotopic mass.In the present invention, the deuterated rate of each appointment D-atom of the compound of institute's labelled synthesis can be at least
3500 times (52.5%), at least 4000 times (60%), at least 4500 times (67.5%), at least 5000 times (75%), extremely
It is 5500 times (82.5%), at least 6000 times (90%), at least 6333.3 times (95%) less, is at least 6466.7 times
(97%), it is at least 6566.7 times (98.5%), at least 6600 times (99%), is at least 6633.3 times (99.5%).
Coordination ferritic (isotopologues) in the present invention refers to only have in terms of chemical constitution in isotopics not
Same compound.In the present invention, the compound of institute's labelled synthesis has identical chemical constitution, only atom at its molecule and forms
In isotopic change.Therefore, in the present invention institute's labelled synthesis can contain considerably less at ad-hoc location too containing deuteride
The hydrogen isotope body of this position, in the present invention, the hydrogen isotope body of certain position in the compound of institute's labelled synthesis measures certainly
Many factors, including deuterated reagent (D2O、D2、NaBD4、LiAlD4Deng) deuterium isotopic purity and introduce deuterium isotope
The validity of synthetic method.But, the amount sum of the hydrogen isotope body of certain position the most this will be less than 49.9%.This
The amount sum of the hydrogen isotope body of certain position in the compound of bright middle institute labelled synthesis will less than 47.5%, 40%, 32.5%,
25%, 17.5%, 10%, 5%, 3%, 1% or 0.5%.
In the present invention, the compound of institute's labelled synthesis has dissimilar chiral centres, asymmetric including caused by deuterium replacement
Chiral centre.In the present invention, the compound of institute's labelled synthesis can be single enantiomer, it is also possible to be mixture of enantiomers.Cause
This, in the present invention, the compound of institute's labelled synthesis may be divided with the form of the form of raceme or single corresponding isomers
Separate out.Single corresponding isomers contains other isomers very small amount of, e.g., less than 25%, 10%, 2% or 1%.
Herein, any each atom being not designated as deuterium exists with its natural isotopic abundance.
Further aspect of the present invention provides a kind of method of compound prepared as shown in I, including:
A) at reducing agent (such as LiAlH4、Et3SiH、NaBH4/AlCl3、NaBD4/AlCl3In the presence of), Formula II compound
It is reduced compound of Formula III;
B) in the presence of alkali (such as n-BuLi), formula III compound reacts with formula IV compound, obtains Formula V compound;
C) at reducing agent (such as Et3SiH/BF3-Et2O、Et3SiD/BF3-Et2O), in the presence of, Formula V compound is reduced into
Compound of formula I.
Formula II compound can be prepared by following method:
Wherein, deuterated 2-bromothiophene can be bought from companies such as Aldrich;Also Pd-Pt-NaBH can be passed through4Combination catalysis
Prepared by the H-D exchange reaction of agent or phosphoric acid catalyzed;Also in the presence of bromide reagent NBS, deuterated thiophene can be changed into 2-bromine deuterium
For thiophene.In the presence of palladium chtalyst reagent, Formula IV compound and Formula VII compound occur C-C coupling reaction to prepare Formula VIII
Compound, the most deuterated or non-deuterated 4-fluorobenzoic boric acid VII can buy from companies such as Combiphos;Deuterated 4-fluorobenzoic boric acid VII
Also (Butters, Mike et al, Angewandte Chemie, International can be prepared by literature method
Edition,49(30),5156-5160,S5156/1-S5156/68;2010).In Lews acid such as AlCl3、ZnO、ZnCl2Deng examination
In the presence of agent, Formula VIII compound and Formula IX compound generation Hooke acylation reaction prepare Formula II compound.
Present invention compound shown in formula I also can be prepared as follows,
Formula X compound can react generation grignard reagent in the presence of magnesium metal, then presses document report with Formula X I
Method (such as Good, James A.D.et al, Journal of Medicinal Chemistry, 56 (5), 1878-1893;
2013) reaction obtains Formula II compound, and it can be further at reducing agent (such as NaBH4Or NaBD4In the presence of), reaction obtains formula
XII compound, then replaces with trim,ethylchlorosilane and obtains Formula X III compound.In the presence of n-BuLi, by Formula X III chemical combination
After thing is transformed into lithium reagent, forms Formula X IV compound with formula IV compound condensation, finally going back original reagent (such as Et3SiH
(D)/BF3-Et2O), in the presence of, reaction obtains compound of formula I.
Further aspect of the present invention provides a kind of pharmaceutical composition, and it contains the compound shown in Formulas I or it pharmaceutically can connect
The salt being subject to, and one or more pharmaceutically acceptable carriers, excipient and/or medium.
" pharmaceutical composition " refers to compound or its salt and the usual acceptance in the art of one or more present invention
For bioactive compound is delivered to organism, such as people, the preparation of carrier, excipient and/or medium.Drug regimen
The purpose of thing is advantageous for giving organism the compound of the present invention.
Term " pharmaceutically acceptable carrier " refers to organism without obvious stimulation effect, and without compromising on this activity
The biologically active of compound and those carriers of performance and diluent." pharmaceutically acceptable excipient and/or medium " refers to
The inert substance of administration that be together administered with active component, beneficially active component." pharmaceutically acceptable carrier, figuration
Agent and/or medium " include but not limited to can be used for people or any carrier of livestock animals, excipient, medium, glidant, sweetened
Agent, diluent, preservative, dyestuff/colouring agent, flavoring reinforcing agent, surfactant, wetting agent, dispersant, disintegrant, suspending
Agent, stabilizer, isotonic agent, solvent or emulsifying agent.The limiting examples of described excipient includes calcium carbonate, calcium phosphate, various
Sugared and each kind of starch, cellulose derivative, gelatin, vegetable oil and polyethylene glycol etc..
In a pure form or with the compounds of this invention of suitable pharmaceutical compositions or its pharmaceutically acceptable salt
Administration can carry out by providing any acceptable mode of administration of medicament of similar applications.The pharmaceutical composition of the present invention can
By the compound of the present invention is prepared with suitable pharmaceutically acceptable supporting agent, diluent or excipient composition, and can
It is configured to solid-state, semisolid, liquid or gaseous state preparation, such as tablet, pill, capsule, pulvis, granule, paste, emulsion, hangs
Floating agent, solution, suppository, injection, inhalant, gel, microballoon and aerosol etc..
The classical pathway giving the compounds of this invention or its pharmaceutically acceptable salt or its pharmaceutical composition include but not
Be limited to be administered orally, rectum, saturating mucous membrane, through enteral administration, or local, percutaneous, suction, parenteral, sublingual, vagina, intranasal, eye
In, intraperitoneal, intramuscular, subcutaneous, intravenous administration.Preferably method of administration is oral administration.
The pharmaceutical composition of the present invention can use method manufacture well-known in the art, such as conventional mixing method, molten
Solution, granulation, dragee method processed, levigate method, emulsion process, freeze-drying etc..
In preferred embodiments, pharmaceutical composition is oral form.For oral administration, can be by activating
Compound mixes with pharmaceutically acceptable carrier well known in the art, excipient and/or medium, prepares this pharmaceutical composition.This
A little carriers, excipient and medium can make the compound of the present invention be formulated into tablet, pill, lozenge, sugar-coat agent, capsule, liquid
Body, gel, slurry agent, suspending agent etc., for the oral administration to patient.
Solid oral composition can be prepared by conventional mixing, filling or tabletting method.Such as, can be by following
Method obtains: mixed with solid excipient by described reactive compound, the mixture of gained of optionally milling, if necessary
Add other suitable assistant agent, then this mixture is processed into particle, obtain tablet or the core of sugar-coat agent.The tax being suitable for
Shape agent includes but not limited to: filler, such as sugar, including lactose, sucrose, mannitol or D-sorbite;Cellulose preparation is the beautifulst
Rice starch, wheaten starch, rice starch and farina;And other material, such as gelatin, tragacanth, methylcellulose, hydroxyl
Propyl methocel, sodium cellulose glycolate and/or polyvinylpyrrolidone;Disintegrant, as PVPP,
Agar or alginic acid, it is possible to use salt, such as mosanom.Can be according to method known in usual medicinal practice optionally to sugar-coat
The core of agent is coated, and especially uses enteric coating.
Pharmaceutical composition could be applicable to parenteral, as the sterile solution agent of suitable unit dosage forms, supensoid agent or
Freeze-drying prods.Suitable excipient, such as filler, buffer or surfactant can be used.
The dosage of the compound shown in formula I can be (such as age, body weight, to be treated according to the health of patient
The type of disease and seriousness) and method of administration and change, and generally at about 0.01-300mg/kg/ days, clinician can basis
Actual conditions eligibly select.
Further aspect of the present invention provides the compound shown in Formulas I or its salt pharmaceutically accepted to benefit from preparation treatment
Purposes in the medicine of the disease of SGLT-2 suppression, described in benefit from the disease of SGLT-2 suppression selected from diabetes, diabetic keratopathy
Retinopathy, diabetic neuropathy, diabetic nephropathy, wound healing delay, insulin resistance, hyperglycemia, height
The rising of insulinemia, aliphatic acid blood concentration, the rising of glycerine blood concentration, hyperlipidemia, obesity, hypertriglyceridemia, X combine
The diseases such as simulator sickness, atherosclerotic or hypertension.
Further aspect of the present invention provide the compound shown in Formulas I or its salt pharmaceutically accepted preparation treatment diabetes,
Purposes in the medicine of the diseases such as diabetic complication, obesity, post-prandial hyperglycemia.Described diabetic complication include but not
It is limited to such as diabetic retinopathy, diabetic neuropathy, diabetic nephropathy etc..
Compound shown in formula I also can be treated above-mentioned disease with the combination of other antidiabetics or delay described
The progress of disease or morbidity, the example of other antidiabetics includes but not limited to: biguanides (such as, melbine or benzene second
Biguanides), glucosidase inhibitor (such as, acarbose, Miglitol), insulin (such as, insulin lispro, sweet essence pancreas
Island element, insulin detemir, insulin aspart, moral paddy insulin), meglitinides (such as, Repaglinide), sulfonylurea (example
As, Glimepiride, glibenclamide, gliclazide, chlorpropamide, Glipizide), thiazolidinediones (such as, troglitazone,
Rosiglitazone, Pioglitazone), PPAR-α/γ dual agonists (such as, Mo Gelieta), GLP-1 receptor stimulating agent (such as, Chinese mugwort
Fill in that peptide, Arg34Lys26-(N-EPSILON-(N-ALPHA-Palmitoyl-L-GAMMA-glutamyl))-GLP-1[7-37]) and DPP4 inhibitor (such as Xi Gelieting, BMS-477118, Egelieting).
Compared with former medicine canagliflozin, the compound shown in Formulas I has more excellent pharmacokinetic property and (internal partly declines
Phase is longer), it is expected to reduce clinical dosage, thus reduces treatment cost to allow more patient be benefited.
Detailed description of the invention:
The following examples can illustrate in greater detail the present invention, but limits the present invention the most in any form.
The preparation of embodiment 1 compound 3
Step 1): [2,3,4,5-D4] preparation of thiophene I-2:
In pressure pipe, weigh thiophene I-1 (5.0g, 59.4mmol), add deuterated water 14ml (700mmol), be cooled to 0
P it is slowly added to after DEG C2O5(28.4g, 200mmol), stirs 5min under room temperature, be heated to 120 DEG C and stir 24 hours.It is cooled to 0
Add water (80ml) after DEG C, use CH2Cl2Extract reactant liquor (3 × 60ml).MgSO4After drying, filtrate is distilled off at ambient pressure
Obtaining oily residue (5.0g) after solvent, under normal pressure, distillation obtains compound I-24.0g, yield 80%.
It is 98.5% that LCMS surveys deuterium content.
HRMS (ESI) m/z:88.0281.
Step 2): the bromo-[3,4,5-D of 2-3] preparation of thiophene I-3
At 0 DEG C, N-bromo-succinimide NBS (2.1g, 11.8mmol) is added to Formulas I-2 compound (0.986g,
AcOD (25ml) 11.2mmol) and CHCl3In solution (25ml), at 50 DEG C, stir reactant mixture 2 hours (until
TLC detects without starting material left).Being cooled to 5-10 DEG C, add water (80ml), separates organic layer, water layer is used CH again2Cl2Extract (3 ×
50ml).Anhydrous MgSO4After drying, filtrate obtains residue, by residue silica gel after under reduced pressure room temperature is distilled off solvent
Column chromatography (EtOac/hexane 6:94) separating-purifying product I-3, yield 80%.
1HNMR (300MHz, DMSO-d6): δ without fragrance hydrogen peak.
HRMS (ESI) m/z:164.9321.
Step 3): 4-is to fluorophenyl [3,4,5-D3] preparation of thiophene I-4
Addition Formulas I-3 compound (13.98g, 85.8mmol) in 1000ml eggplant-shape bottle, 4-fluorobenzoic boric acid (12.0g,
85.8mmol), Pd (PPh3)4(0.96g, 0.85mmol), glycol dimethyl ether 150ml, Na2CO3(27.3g, 258mmol's)
Aqueous solution 150ml, is heated to 80 DEG C of reaction 3h.Room temperature is down to by reactant mixture, pours in frozen water, CH2Cl2Extraction (2 ×
100ml), organic layer, anhydrous MgSO are isolated4It is dried.Steaming solvent, crude product column chromatography for separation obtains white solid I-
413.68g, yield 90.8%.
1HNMR (300MHz, DMSO-d6): δ 7.67~7.71 (m, 2H), 7.22~7.28 (m, 2H).
HRMS (ESI) m/z:181.0437.
It is 98.5% that LCMS surveys deuterium content.
Step 4): 2-(bromo-2 methyl-benzyls of 5-)-5-(4-fluorophenyl) [3,4-D2] preparation of thiophene I-7
(bromo-2 aminomethyl phenyls of 5-) (5-(4-fluorophenyl) [3,4-D2] thiophene-2-base ketone I-6:500ml eggplant-shape bottle adds
I-4 (13.86g, 77.8mmol), 2-methyl-5-bromo-benzoyl chloride I-5 (19.08g, 81.7mmol), CH2Cl2250ml dissolves, and 0
AlCl is added at DEG C3(11.4g, 85.6mmol), is warmed to room temperature reaction overnight after 30min.Reactant mixture is poured in frozen water,
CH2Cl2Extraction (2 × 100ml), the anhydrous MgSO of organic layer4It is dried.Steam solvent, in mixture, add n-hexane, filter, filter
Cake n-hexane is washed, and is dried to obtain faint yellow solid I-624.3g, yield 83.2%.
1HNMR (300MHz, CDCl3): δ 7.62~7.66 (2H, m), 7.57 (1H, s), 7.49~7.52 (1H, dd, J1=
8.2Hz,J2=1.8Hz), 7.09~7.18 (3H, m), 2.33 (3H, s).
13C-NMR (300MHz, CDCl3): δ 188.32,164.99,161.68,153.23,142.62,140.06,
135.36,133.14,132.71,130.47,129.48,129.43,128.26,128.15,124.00,118.80,116.41,
116.12,19.15。
HRMS (ESI) m/z:375.9908.
2-(bromo-2 methyl-benzyls of 5-)-5-(4-fluorophenyl) [3,4-D2] thiophene I-7:
Addition I-6 (10.0g, 26.5mmol) in method one: 500ml three-necked bottle, triethyl silicane (18.5ml,
106.5mmol), CH2Cl250ml, acetonitrile 50ml, be down to 0 DEG C.Boron trifluoride ether solution it is slowly added dropwise in reactant mixture
(12.5ml, 100.5mmol), finishes, and is warmed to room temperature reaction overnight.Ice bath downhill reaction thing adds saturated NaHCO3Solution
50ml, CH2Cl2Extraction, the anhydrous MgSO of organic layer4It is dried.Steam solvent, obtain yellow solid I-78.9g, yield 93.6%.
Method two: 100ml bottle adds I-6 (2.0g, 5.3mmol), oxolane 20ml, NaBH4(0.2g,
5.3mmol), it is down to 0 DEG C, adds AlCl3(0.77g, 5.8mmol), rises to 70 DEG C of reaction 5h.Pour reactant mixture into frozen water
In, EA extracts, and steams solvent, obtains white solid I-7 (1.85g), yield 96%.
1HNMR (300MHz, CDCl3): δ 7.47 (2H, dd, J1=5.4Hz, J2=8.4Hz, Ph), 7.33 (1H, s, Ph),
7.29 (1H, d, J=8.1Hz, Ph), 6.99~7.04 (3H, m, Ph), 4.06 (2H, s, Ph-CH2-thio),2.26(3H,s,
Me)。
13C-NMR (300MHz, CDCl3): δ 163.71,160.51,142.10,140.33,135.28,132.16,
130.74,130.69,129.89,127.20,127.10,122.64,119.65,115.87,115.58,33.78,18.98。
HRMS (ESI) m/z:362.0113.
Step 5): (3R, 4S, 5S, 6R)-2-3-((5-(4-fluorophenyl) [3 ', 4 '-D2] thiophene-2-base) methyl)-4-first
Phenyl) preparation of-6-(methylol)-2-methoxyl group tetrahydrochysene-2H-pyrans-3,4,5-triol I-9
(3R, 4S, 5R, 6R)-3,4,5-three (trimethyl silicane alkoxyl) methyl) tetrahydrochysene-2H-pyran-2-one I-8: by Portugal
Grape saccharic acid lactone (30g, 168.5mmol), anhydrous tetrahydro furan (250ml) are added sequentially in 1L there-necked flask, add N-first
Base morpholine (150ml, 1.35mol).Reaction bulb is transferred in-20 degree low temperature baths, by trim,ethylchlorosilane under nitrogen protection
(129ml, 1.01mol) is slowly dropped in reactant liquor in constant pressure funnel, and whole dropping process continues 30 minutes.Finish, continue
Reaction bulb was transferred in oil bath pan after 15 minutes by continuous low-temp reaction, opens and is heated to reactant liquor backflow.TLC detection after 2 hours
Display raw material entirely without residue, basic all for the purpose of product.After room temperature is down to by reaction bulb, addition 600ml petroleum ether, 400ml water,
Being sufficiently stirred for rear separatory, TLC display water layer is without obvious product, and organic layer is containing purpose product and a small amount of N-methylmorpholine.Organic layer
Add 300ml water, 25g potassium dihydrogen phosphate, be sufficiently stirred for rear separatory.Organic layer still has trace N-methylmorpholine, again adds
200ml water, 15g potassium dihydrogen phosphate, be sufficiently stirred for rear separatory, and TLC shows without obvious N-methylmorpholine and other impurity.Organic layer
Steaming to obtain pale yellow oily liquid body with anhydrous sodium sulfate (100g) rotation after drying, silica gel column chromatography purifies, petroleum ether-ethyl acetate
(20:1, V/V), obtains colourless oil liquid I-8 (65.5g, 140.2mmol), yield 83.2%.
(3R, 4S, 5S, 6R)-2-3-((5-(4-fluorophenyl) [3 ', 4 '-D2] thiophene-2-base) methyl)-4-tolyl)-
6-(methylol)-2-methoxyl group tetrahydrochysene-2H-pyrans-3, in 4,5-triol I-9:100ml three-necked bottles add I-7 (1.85g,
5mmol), THF (Non-aqueous processing) 15ml, toluene (Non-aqueous processing) 15ml, N2Under protection, at-78 DEG C, it is slowly added dropwise n-BuLi
Hexane solution (2.13ml, 5.4mmol), react 20min.In reactant mixture, dropping is dissolved in 5ml toluene (anhydrous place
Reason) Formulas I-8 compound (2.12g, 4.5mmol), 5min adds.Reaction 30min, adds the methyl being dissolved in 10ml absolute methanol
Sulfonic acid solutions (1.29g, 13.5mmol), 5min adds.It is warmed to room temperature reaction overnight.Ice bath downhill reaction thing add saturated
NaHCO3Solution 20ml, ethyl acetate extracts, the anhydrous MgSO of organic layer4It is dried.Steaming solvent, it is solid that column chromatography for separation obtains white
Body I-9 (0.8g), yield 38%.
1H-NMR (300MHz, DMSO-d6): δ 7.55~7.60 (2H, m, Ph), 7.43 (1H, s, Ph), 7.33 (1H, d, J
=7.9Hz, Ph), 7.13~7.22 (3H, m, Ph), 4.93 (1H, d, J=5.3Hz, OH), 4.68 (1H, d, J=4.9Hz,
OH), 4.63 (1H, d, J=7.3Hz, OH), 4.50 (1H, t, J=5.8Hz, OH), 4.11~4.16 (2H, dd, J1=
15.7Hz,J2=29.2Hz, Ph-CH2-thio), 3.73~3.79 (1H, m, sugar), 3.51~3.64 (2H, m, sugar),
3.37~3.41 (1H, m, sugar), 3.22~3.26 (1H, m, sugar), 2.96 (3H, s, OMe), 2.90~2.92 (1H, m,
sugar),2.26(3H,s,Me)。
13C-NMR (300MHz, DMSO-d6): δ 162.94,159.70,143.69,140.05,137.22,136.90,
135.09,130.54,129.37,128.74,126.94,126.83,126.04,115.97,115.68,100.83,77.03,
74.33,73.80,70.21,60.94,48.18,33.59,18.66。
HRMS (ESI) m/z:476.1638.
Step 6): (2S, 3R, 4R, 5S, 6R)-2-3-((5-(4-fluorophenyl) [3 ', 4 '-D2] thiophene-2-base) methyl)-
4-tolyl) preparation of-6-(methylol)-tetrahydrochysene-2H-pyrans-3,4,5-triol 3
Addition I-9 (0.5g, 1.05mmol) in 25ml three-necked bottle, triethyl silicane (0.72ml, 4.18mmol),
8mlCHCl2, N2Protection, is down to-70 DEG C.Be slowly added dropwise in reactant mixture boron trifluoride ether solution (0.5ml,
3.99mmol).Rise to 0 DEG C of reaction 2h.Saturated NaHCO is added in reactant mixture3Solution 10ml, ethyl acetate extracts, has
The anhydrous MgSO of machine layer4It is dried.Steaming solvent, column chromatography for separation obtains white solid 3 (0.3g), yield 65%.
1H-NMR (300MHz, DMSO-d6): δ 7.56~7.60 (2H, dd, J1=8.6Hz, J2=5.5Hz, Ph), 7.10
~7.25 (5H, m, Ph), 4.83 (2H, s, OH), 4.65 (1H, s, OH), 4.35 (1H, s, OH), 4.12 (2H, s, Ph-CH2-
Thio), 3.98 (1H, d, J=9.2Hz, sugar), 3.69~3.73 (1H, m, sugar), 3.47 (1H, m, sugar), 3.18
~3.28 (4H, m, sugar), 2.26 (3H, s, Me).
13C-NMR (300MHz, DMSO-d6): δ 162.92,159.68,143.47,140.16,138.15,137.26,
134.83,130.49,129.56,128.98,126.93,126.82,126.15,123.32,115.91,115.62,81.24,
81.10,78.44,74.62,70.41,61.41,33.33,18.70。
HRMS (ESI) m/z:446.1536.
The preparation of embodiment 2 compound 1
Step 1): (5-bromo-2-aminomethyl phenyl) (preparation of 5-(4-fluorophenyl) thiophene-2-base ketone II-4
The bromo-5-of 2-(4-fluorophenyl) thiophene II-2: compound II-1 (4.0g, 22.47mmol) is joined 100ml single port
In flask, add dichloromethane (40ml), open magnetic agitation, under condition of ice bath add N-bromosuccinimide (4.0g,
22.47mmol).It is stirred overnight under room temperature condition after continuing stirring 20 minutes.TLC shows without obvious starting material left and impurity.
Reactant liquor reduced pressure concentration removes major part methylene chloride, is subsequently adding 80ml petroleum ether and is sufficiently stirred for 20 minutes, and decompression is taken out
Filter, filtrate obtains about 6.9g white solid (containing part succinimide) after concentrating.Solid rejoins in 50ml petroleum ether and fills
Reduce pressure after dividing stirring 20 minutes suction filtration again, is dried and obtains 5.70g snow-white solid II-2, yield after filtrate reduced in volume
95.3%.
1H-NMR(CDCl3, 300MHz): δ 7.44-7.48 (m, 2H), 7.00-7.09 (m, 3H), 6.95-6.97 (m, 1H).
13C-NMR(CDCl3, 300MHz): δ 164.14,160.85,144.75,130.84,127.40,127.30,
123.24,116.12,115.83,111.33.
5-bromo-N-methoxyl group-N, 2-dimethylbenzamide II-3: by 2-methyl-5-bromobenzoic acid (2.15g, 10mmol)
Join in 50ml single port flask, be sequentially added into dichloromethane (25ml), N, O-dimethyl hydroxylamine hydrochloride (1.07g,
11mmol), dicyclohexylcarbodiimide (2.26g, 11mmol), I-hydroxybenzotriazole one water thing (1.48g, 11mmol).Nitrogen
Triethylamine (1.67ml, 12mmol) is added under gas shielded.Stirred overnight at room temperature, TLC display raw material 2-methyl-5-bromobenzoic acid is still
Have relatively multiresidue, add N, O-dimethyl hydroxylamine hydrochloride (1.07g, 11mmol), dicyclohexylcarbodiimide (1.50g,
7.3mmol), triethylamine (1.0ml, 7.2mmol).After being stirred at room temperature 5 hours, TLC display raw material is without substantially residue.Reactant liquor subtracts
Pressure suction filtration, filter cake dichloromethane washes twice (5ml × 2).Filtrate is sequentially added into 20ml dichloromethane and 20ml water, after separatory
Water layer adds the extraction of 10ml dichloromethane.Merging organic layer, saturated aqueous common salt washs, and anhydrous sodium sulfate reduces pressure after drying and distills
Product crude product.Crude product silica gel column chromatography is purified, and petroleum ether-ethyl acetate (20:1, V/V) elutes, and obtains light yellow viscous liquid
II-3 (1.42g, 5.48mmol), yield 54.8%.
1H-NMR(CDCl3, 300MHz): δ 7.39-7.41 (m, 2H), 7.06-7.09 (m, 1H), 3.51 (s, 3H), 3.30
(s, 3H), 2.27 (s, 3H).
13C-NMR(CDCl3, 300MHz): δ 136.99,134.82,133.88,132.05,131.77,128.95,
118.78,61.14,26.85,18.58.
(bromo-2 aminomethyl phenyls of 5-) (5-(4-fluorophenyl) thiophene-2-base ketone II-4: by compound II-2 (0.386g,
1.5mmol) join in dry 15ml there-necked flask, add the magnesium chips (0.096g, 6.0mmol) that watery hydrochloric acid activated, nitrogen
Air in displacement reaction bottle.Absolute ether (3ml) syringe is injected in reaction bulb, opens and be heated to solvent refluxing.Will be few
Being permitted iodine grain (5) to be added rapidly in reactant liquor, reactant liquor is dark-brown, continuation heating stir about reactant liquor color after 5 minutes
Gradually become shallower as to colourless.Continue reaction at reflux and be directly used in grignard addition reaction after 15 minutes.By compound II-3
(0.39g, 1.5mmol) is dissolved in anhydrous tetrahydro furan (2ml), air in nitrogen displacement reaction bottle.Lattice will be made by oneself under condition of ice bath
Family name's reagent (3ml, 0.5M in Ether) is slowly dropped in reaction bulb.Ice bath stirring at normal temperature is removed, after 2 hours after 5 minutes
TLC shows a large amount of product and generates (standard sample comparison), is joined by reactant liquor in frozen water (6g), stands and divide after being sufficiently stirred for
Liquid, water layer dichloromethane extracts (2 × 15ml).Merge organic layer, saturated aqueous common salt washing (3 × 10ml), anhydrous sodium sulfate
Pale solid is steamed to obtain in dried rotation.Above-mentioned solid joins making beating stirring 30 minutes in 50ml petroleum ether, and reduce pressure suction filtration, filter
Cake obtains off-white color solid II-4 (0.402g) after drying.
1H-NMR(CDCl3, 300MHz): δ 7.62-7.66 (m, 2H), 7.57 (d, J=1.5Hz, 1H), 7.49-7.52
(dd, J1=1.9Hz, J2=5.2Hz, 1H), 7.37 (d, J=3.9Hz, 1H), 7.25 (d, J=3.8Hz, 1H), 7.09-7.18
(m, 3H), 2.33 (s, 3H).
13C-NMR(CDCl3, 300MHz): δ 118.29,164.99,153.27,140.08,136.68,135.33,
133.12,132.07,130.46,128.25,128.14,124.09,118.80,116.39,116.10,19.13.
Step 2): 2-(the bromo-2 methyl [1,1-D of 5-2] benzyl) preparation of-5-(4-fluorophenyl) thiophene II-5:
Compound II-4 (2.06g, 5.51mmol) is joined in 50ml there-necked flask, adds acetonitrile (20ml), nitrogen
Air in displacement reaction bottle, rapidly join deuterated sodium borohydride (0.56g, 13.78mmol), alchlor (1.10g,
8.26mmol), being transferred to by reaction bulb in 55 degree of oil bath pans, have a large amount of bubble to escape, after 10 minutes, TLC display raw material reacts
Completely.Reaction bulb is cooled to room temperature, is slowly added into by reactant liquor in 30ml frozen water mixed liquor under stirring, and a large amount of whites are solid
Body separates out, and reduce pressure suction filtration, and filter cake 10ml water washes twice.After filtration cakes torrefaction off-white color solid II-5 (1.64g,
4.52mmol, yield 82.0%).
1HNMR (300MHz, CDCl3): δ 7.45~7.49 (2H, m, Ph), 7.24~7.28 (1H, m, thio), 7.30~
7.34 (1H, m, Ph), 6.99~7.05 (4H, m, Ph), 6.66~6.67 (1H, d, J=3.3Hz, thio), 2.26 (3H, s,
Me)。
13C-NMR(CDCl3, 300MHz): δ 163.79,160.52,142.12,141.86,140.24,135.26,
132.15,132.02,129.89,127.21,127.11,126.22,122.72,119.65,115.85,115.56,18.94,
15.07。
HRMS (ESI) m/z:362.0111.
Step 3): (3R, 4S, 5S, 6R)-2-3-((5-(4-fluorophenyl) thiophene-2-base) [1,1-D2] methyl)-4-toluene
Base)-6-(methylol)-2-methoxyl group tetrahydrochysene-2H-pyrans-3, the preparation of 4,5-triol II-6
Compound II-5 (1.41g, 3.88mmol) is joined 100ml be dried in there-necked flask, nitrogen displacement reaction bottle
Middle air.Successively dry toluene (12ml), anhydrous tetrahydro furan (18ml) are injected reaction bulb with syringe under nitrogen protection.Will
Reaction bulb is placed in the bath of-78 DEG C of low temperature, and in question response liquid, temperature drop is to after-78 DEG C, by n-butyllithium solution (1.71ml,
4.27mmol, 2.5M) it is slowly injected in reactant liquor, reactant liquor quickly becomes navy blue, and whole dropping process continues 3 minutes, instead
In answering liquid, temperature is less than-66 DEG C.After 30 minutes, by be dissolved in 6ml dry toluene TMS-glucolactone (1.81g,
During 3.88mmol) solution is slowly injected into reactant liquor, whole dropping process continues 3 minutes, and in keeping reactant liquor, temperature is less than-66 DEG C.
Reactant liquor continues to stir 2 hours in-78 DEG C of low temperature baths.Absolute methanol by pyrovinic acid (1.49g, 15.52mmol)
(12ml), during solution is slowly injected into reaction bulb, in keeping reactant liquor, temperature is less than-60 DEG C.Drip complete, reaction bulb is placed in outdoor
Under the conditions of continue stirring reaction 3 hours.Under condition of ice bath, 80ml saturated sodium bicarbonate solution is slowly added in reactant liquor, fills
Dividing separatory after stirring, water layer 80ml ethyl acetate is extracted twice, and merges organic layer, and saturated nacl aqueous solution (3 × 15ml) is washed
Washing, anhydrous sodium sulfate revolves after drying and steams to obtain off-white color solid.Crude product silica gel column chromatography is purified, and acetate-methanol elutes
(10:1, V/V), obtains white solid II-6 (1.40g, 2.94mmol, yield 75.8%).
1H-NMR (300MHz, DMSO-d6): δ 7.55~7.60 (2H, m, Ph), 7.44 (1H, s, Ph), 7.33~7.35
(1H, d, J=7.8Hz, Ph), 7.26~7.27 (1H, d, J=3.3Hz, thio), 7.13~7.22 (3H, m, Ph), 6.76~
6.77 (1H, d, J=3.4Hz, thio), 4.95 (1H, d, 5.3Hz, OH), 4.71 (1H, d, 4.9Hz, OH), 4.65 (1H, d,
7.2Hz, OH), 4.53 (1H, t, 5.8Hz, OH), 3.75~3.80 (1H, m, sugar), 3.52~3.65 (2H, m, sugar),
3.39~3.44 (1H, m, sugar), 3.20~3.28 (1H, m, sugar), 2.99 (3H, s, OMe), 2.26 (3H, s, Me).
13C-NMR (300MHz, DMSO-d6): δ 162.94,159.70,143.68,140.13,137.20,136.81,
135.05,130.53,129.34,128.70,126.94,126.83,126.12,126.01,123.33,115.95,115.66,
100.81,77.03,74.32,73.78,70.22,60.94,48.16,18.63。
HRMS (ESI) m/z:476.1638.
Step 4): (2S, 3R, 4R, 5S, 6R)-2-3-((5-(4-fluorophenyl) thiophene-2-base) [1,1-D2] methyl)-4-
Tolyl) preparation of-6-(methylol)-tetrahydrochysene-2H-pyrans-3,4,5-triol 1
Compound II-6 (1.20g, 2.52mmol) is joined in tri-mouthfuls of reaction bulbs of 50ml, be sequentially added into dichloromethane
(20ml), triethyl silicane (1.20ml, 7.56mmol).Reaction bulb is placed in-50 DEG C of low temperature baths.By BFEE
(0.96ml, 7.56mmol) solution is slowly injected in reaction bulb.Treat that boron trifluoride ether solution finishes, reaction bulb is placed in room temperature
Under the conditions of be stirred overnight.Being slowly added in reactant liquor by 30ml saturated sodium bicarbonate solution, be sufficiently stirred for rear separatory, water layer is used
30ml ethyl acetate extracts, and merges organic layer, and anhydrous sodium sulfate revolves steaming after drying and obtains off-white color solid.Crude product silica gel column chromatography
Purify, acetate-methanol wash-out (10:1, V/V), obtain white solid 1 (900mg).
1H-NMR (300MHz, DMSO-d6): δ 7.59 (2H, dd, J1=5.4Hz, J2=8.7Hz, Ph), 7.27 (1H, d, J
=3.5Hz, thio), 7.13~7.22 (5H, m), 6.80 (1H, d, J=3.5Hz, thio), 4.90 (2H, d, J=4.4Hz,
OH), 4.71 (1H, d, J=5.5Hz, OH), 4.42 (1H, t, J=5.7Hz, OH), 3.97 (1H, d, J=9.2Hz, sugar),
3.67~3.73 (1H, m, sugar), 3.40~3.48 (1H, m, sugar), 3.12~3.27 (4H, m, sugar), 2.26 (s,
3H)。
13C-NMR (300MHz, DMSO-d6): δ 162.94,159.70,143.49,140.18,138.16,137.22,
134.85,130.51,129.57,128.98,126.96,126.85,126.27,126.17,123.32,115.94,115.65,
81.26,81.13,78.45,74.63,70.42,61.42,18.71。
HRMS (ESI) m/z:446.1536.
The preparation of embodiment 3 compound 4
Step 1): 2-[D3] preparation of methyl 5-bromobenzoic acid III-2:
Weighing 2-methyl 5-bromobenzoic acid III-1 (5.0g, 23.3mmol) in microwave pressure-resistant pipe, NaOD (40%,
28.0mmol), add deuterated water 24ml (24g, 1.2mol), stir 30 minutes under room temperature, be heated to 160 DEG C and stir 4 hours.Remove
Remove heavy water, add deuterated water 24ml.It is heated to 160 DEG C stir 2 hours.Add DCl after being cooled to 0 DEG C and adjust about pH=3, use
CH2Cl2Extract reactant liquor (3 × 30ml).MgSO4After drying, filtrate obtains oily residue after solvent is under reduced pressure distilled off
III-2 (4.6g, yield 90%).
1H NMR(CDCl3): δ 7.70 (m, 2H), 7.25 (m, 2H).
HRMS (ESI) m/z:181.0439.
Step 2): (5-bromo-2-[D3] aminomethyl phenyl) (the preparation of 5-(4-fluorophenyl) thiophene-2-base ketone III-3
Method one
With reference to embodiment 1 step 4) prepare compound III-3.
1HNMR (300MHz, CDCl3): δ 7.62~7.66 (2H, m), 7.57 (1H, m), 7.49~7.52 (1H, dd, J1=
8.2Hz, J2=1.8Hz), 7.36~7.38 (1H, d, J=3.8Hz), 7.24~7.25 (1H, d, J=3.8Hz), 7.09~
7.18 (3H, m).
HRMS (ESI) m/z:376.9961.
Method two
In microwave pressure-resistant pipe, add compound II-4 (5.0g, 13.3mmol), NaOD (3.0mmol), add deuterated water
24ml (24g, 1.2mol), is heated to 160 DEG C and stirs 4 hours.Remove heavy water, add fresh deuterated water 12ml and THF
(12ml).It is heated to 160 DEG C stir 4 hours.It is cooled to room temperature, uses CH2Cl2Extract reactant liquor (3 × 30ml).MgSO4It is dried
After, filtrate obtains oily residue III-3 (4.3g, yield 84%) after solvent is under reduced pressure distilled off.
Step 3): 2-(5-bromo-2-[D3] methyl-benzyl) preparation of-5-(4-fluorophenyl) thiophene III-4
Joining in there-necked flask by compound III-3 (2.0g, 5.31mmol), add THF (20ml), nitrogen displacement is anti-
Answer air in bottle, rapidly join aluminium lithium hydride (0.50g, 13.3mmol), reaction bulb is transferred in 55 degree of oil bath pans, have a large amount of
Bubble escapes, and after 10 minutes, TLC display raw material has reacted complete.Reaction bulb is cooled under 0 DEG C, stirring join 0.5ml
Frozen water, 0.5ml 15%NaOH and 1.5ml frozen water are in reaction mixture, and after stirring 2 hours, a large amount of white solids separate out, and subtract
Pressure suction filtration, filter cake 10ml THF washes twice.Filtrate is distilled off THF after drying, obtain off-white color solid III-4 (1.64g,
4.52mmol, yield 82.0%).
1HNMR (300MHz, CDCl3): δ 7.45~7.49 (2H, m), 7.24~7.34 (2H, m), 6.99~7.05 (4H,
M), 6.66~6.67 (1H, d, J=3.3Hz), 4.04 (2H, s).
HRMS (ESI) m/z:363.0112.
Step 4): (3R, 4S, 5S, 6R)-2-3-((5-(4-fluorophenyl) thiophene-2-base) methyl)-4-[D3] tolyl)-
The preparation of 6-methylol-2-methoxyl group tetrahydrochysene-2H-pyrans-3,4,5-triol III-5
With reference to embodiment 1 step 5) prepare compound III-5.
1HNMR (300MHz, DMSO-d6): δ 7.55~7.60 (2H, m, Ph), 7.42 (1H, s, Ph), 7.32~7.34
(1H, d, J=7.0Hz, Ph), 7.26~7.27 (1H, d, J=3.4Hz, thio), 7.13~7.22 (3H, m, Ph), 6.76~
6.77 (1H, d, J=3.3Hz, thio), 4.92 (1H, s, OH), 4.50~4.64 (3H, m, OH), 4.11,4.16 (each 1H,
S, Ph-CH2-thio), 3.74~3.77 (1H, m, sugar), 3.51~3.62 (2H, m, sugar), 3.37 (1H, m,
Sugar), 3.17~3.25 (1H, m, sugar), 2.96 (3H, s, OMe), 2.90 (1H, s, sugar).
HRMS (ESI) m/z:477.1705.
Step 5): (2S, 3R, 4R, 5S, 6R)-2-3-((5-(4-fluorophenyl) thiophene-2-base) methyl)-4-[D3] toluene
Base) preparation of-6-(methylol)-tetrahydrochysene-2H-pyrans-3,4,5-triol 4
With reference to embodiment 1 step 6) prepare compound 4.
1HNMR (300MHz, DMSO-d6): δ 7.56~7.61 (2H, dd, J1=8.6Hz, J2=5.5Hz, Ph), 7.26~
7.27 (1H, d, J=3.5Hz, thio), 7.10~7.22 (5H, m, Ph), 6.78~6.80 (1H, d, J=3.4Hz, thio),
4.89~4.90 (2H, d, J=4.4Hz, OH), 4.69~4.71 (1H, d, J=5.6Hz, OH), 4.39~4.43 (1H, t, J=
5.7Hz, OH), 4.11,4.12 (each 1H, s, Ph-CH2-thio), 3.94~3.98 (1H, d, J=9.3Hz, sugar),
3.67~3.72 (1H, m, sugar), 3.40~3.47 (1H, m, sugar), 3.12~3.27 (4H, m, sugar).
HRMS (ESI) m/z:447.1591.
The preparation of embodiment 4 compound 5
Step 1): the 2-(bromo-2 [D of 5-3] methyl [1 ', 1 '-D2] benzyl) preparation of-5-(4-fluorophenyl) thiophene IV-1
With reference to embodiment 2 step 2) prepare compound IV-1.
1HNMR (300MHz, CDCl3): δ 7.44~7.47 (2H, m), 7.23~7.34 (2H, m), 6.97~7.05 (4H,
M), 6.64~6.67 (1H, d, J=3.3Hz).
HRMS (ESI) m/z:365.0237.
Step 2): (3R, 4S, 5S, 6R)-2-3-((5-(4-fluorophenyl) thiophene-2-base) [1,1-D2] methyl)-4-[1,
1,1-D3] tolyl) preparation of-6-(methylol)-2-methoxyl group tetrahydrochysene-2H-pyrans-3,4,5-triol IV-2
With reference to embodiment 1 step 5) prepare compound IV-2.
1HNMR (300MHz, DMSO-d6): δ 7.54~7.61 (2H, m, Ph), 7.42 (1H, s, Ph), 7.32~7.34
(1H, d, J=7.0Hz, Ph), 7.26~7.27 (1H, d, J=3.4Hz, thio), 7.13~7.22 (3H, m, Ph), 6.76~
6.77 (1H, d, J=3.3Hz, thio), 4.92 (1H, s, OH), 4.50~4.64 (3H, m, OH), 3.74~3.77 (1H, m,
Sugar), 3.51~3.62 (2H, m, sugar), 3.37 (1H, m, sugar), 3.17~3.25 (1H, m, sugar), 2.96
(3H, s, OMe), 2.90 (1H, s, sugar).
HRMS (ESI) m/z:479.1804.
Step 3): (2S, 3R, 4R, 5S, 6R)-2-3-((5-(4-fluorophenyl) thiophene-2-base) [1,1-D2] methyl)-4-
[1,1,1-D3] tolyl) preparation of-6-(methylol)-tetrahydrochysene-2H-pyrans-3,4,5-triol 5
With reference to embodiment 1 step 6) prepare compound 5.
1HNMR (300MHz, DMSO-d6): δ 7.55~7.60 (2H, dd, J1=8.6Hz, J2=5.5Hz, Ph), 7.26~
7.27 (1H, d, J=3.5Hz, thio), 7.10~7.22 (5H, m, Ph), 6.78~6.80 (1H, d, J=3.4Hz, thio),
4.89~4.90 (2H, d, J=4.4Hz, OH), 4.69~4.71 (1H, d, J=5.6Hz, OH), 4.39~4.43 (1H, t, J=
5.7Hz, OH), 3.94~3.98 (1H, d, J=9.3Hz, sugar), 3.67~3.72 (1H, m, sugar), 3.40~3.47
(1H, m, sugar), 3.12~3.27 (4H, m, sugar).
HRMS (ESI) m/z:449.1771.
The preparation of embodiment 5 compound 13
Step 1): 2-(5-bromo-2-[D3] methyl-benzyl)-5-(4-fluorophenyl) [3,4-D2] thiophene V-2:
(5-bromo-2-[D3] aminomethyl phenyl) (5-(4-fluorophenyl) [3,4-D2] thiophene-2-base ketone V-1: with reference to embodiment 1 step
Rapid 4) method prepares compound V-1.
1HNMR (300MHz, CDCl3): δ 7.61~7.65 (2H, m), 7.57 (1H, m), 7.49~7.52 (1H, dd, J1=
8.2Hz, J2=1.8Hz), 7.09~7.18 (3H, m).
HRMS (ESI) m/z:379.0040.
2-(5-bromo-2-[D3] methyl-benzyl)-5-(4-fluorophenyl) [3,4-D2] thiophene V-2: with reference to embodiment 3 step 3)
Method prepare compound V-2.
1HNMR (300MHz, CDCl3): δ 7.45~7.49 (2H, m), 7.24~7.34 (2H, m), 6.99~7.05 (4H,
M), 6.66~6.67 (1H, d, J=3.3Hz), 4.06 (2H, s).
HRMS (ESI) m/z:365.0247.
Step 2): (3R, 4S, 5S, 6R)-2-3-((5-(4-fluorophenyl) [3 ', 4 '-D2] thiophene-2-base) methyl)-4-
[D3] tolyl)-6-(methylol)-2-methoxyl group tetrahydrochysene-2H-pyrans-3,4,5-triol V-3
With reference to embodiment 1 step 5) method prepare compound V-3.
1HNMR (300MHz, DMSO-d6): δ 7.55~7.60 (2H, m, Ph), 7.42 (1H, s, Ph), 7.32~7.34
(1H, d, J=7.0Hz, Ph), 7.13~7.22 (3H, m, Ph), 4.92 (1H, s, OH), 4.50~4.64 (3H, m, OH),
4.11,4.16 (each 1H, s, Ph-CH2-thio), 3.74~3.77 (1H, m, sugar), 3.51~3.62 (2H, m,
Sugar), 3.37 (1H, m, sugar), 3.17~3.25 (1H, m, sugar), 2.96 (3H, s, OMe), 2.90 (1H, s,
sugar)。
13C-NMR (DMSO, 300MHz): δ 162.97,159.73,143.80,140.16,137.23,136.90,
135.10,130.55,129.38,128.76,126.96,126.86,126.14,126.05,123.35,115.59,115.69,
100.84,77.06,74.36,73.81,70.25,60.98,48.20,33.63.
HRMS (ESI) m/z:476.1638.
Step 3): (2S, 3R, 4R, 5S, 6R)-2-3-((5-(4-fluorophenyl) [3 ', 4 ' D2] thiophene-2-base) methyl)-4-
[1,1,1-D3] tolyl)-6-(methylol)-tetrahydrochysene-2H-pyrans-3,4,5-triol 13.
With reference to embodiment 1 step 6) method prepare compound 13.
1HNMR (300MHz, DMSO-d6): δ 7.56~7.61 (2H, dd, J1=8.6Hz, J2=5.5Hz, Ph), 7.10~
7.22 (5H, m, Ph), 4.89~4.90 (2H, d, J=4.4Hz, OH), 4.69~4.71 (1H, d, J=5.6Hz, OH), 4.39
~4.43 (1H, t, J=5.7Hz, OH), 4.11,4.12 (each 1H, s, Ph-CH2-thio), 3.94~3.98 (1H, d, J=
9.3Hz, sugar), 3.67~3.72 (1H, m, sugar), 3.40~3.47 (1H, m, sugar), 3.12~3.27 (4H, m,
sugar)。
HRMS (ESI) m/z:449.1701.
The preparation of embodiment 6 compound 10
Step 1): 2-(5-bromo-2-[D3] methyl [D2] benzyl)-5-(4-fluorophenyl) [3,4-D2] thiophene VI-1
With reference to embodiment 2 step 2) method prepare compound VI-1.
1HNMR (300MHz, CDCl3): δ 7.45~7.49 (2H, m), 7.23~7.34 (2H, m), 6.97~7.05 (3H,
m)。
HRMS (ESI) m/z:367.0411.
Step 2): (3R, 4S, 5S, 6R)-2-3-((5-(4-fluorophenyl) [3 ', 4 '-D2] thiophene-2-base) [D2] methyl)-
4-[D3] tolyl)-6-(methylol)-2-methoxyl group tetrahydrochysene-2H-pyrans-3,4,5-triol VI-2.
With reference to embodiment 2 step 3) prepare compound VI-2.
1HNMR (300MHz, DMSO-d6): δ 7.53~7.60 (2H, m, Ph), 7.42 (1H, s, Ph), 7.32~7.34
(1H, d, J=7.0Hz, Ph), 7.13~7.22 (3H, m, Ph), 4.92 (1H, s, OH), 4.50~4.64 (3H, m, OH), 3.74
~3.77 (1H, m, sugar), 3.51~3.62 (2H, m, sugar), 3.37 (1H, m, sugar), 3.17~3.25 (1H, m,
Sugar), 2.95 (3H, s, OMe).
HRMS (ESI) m/z:481.1912.
Step 3): (2S, 3R, 4R, 5S, 6R)-2-3-((5-(4-fluorophenyl) [3 ', 4 ' D2] thiophene-2-base) [D2] first
Base)-4-[1,1,1-D3] tolyl)-6-(methylol)-tetrahydrochysene-2H-pyrans-3,4,5-triol 10
With reference to implement 1 step 6) method prepare compound 10.
1HNMR (300MHz, DMSO-d6): δ 7.56~7.61 (2H, dd, J1=8.6Hz, J2=5.5Hz, Ph), 7.10~
7.22 (5H, m, Ph), 4.89~4.90 (2H, d, J=4.4Hz, OH), 4.69~4.71 (1H, d, J=5.6Hz, OH), 4.39
~4.43 (1H, t, J=5.7Hz, OH), 3.94~3.98 (1H, d, J=9.3Hz, sugar), 3.67~3.72 (1H, m,
Sugar), 3.40~3.47 (1H, m, sugar), 3.12~3.27 (4H, m, sugar).
HRMS (ESI) m/z:451.1814.
The preparation of embodiment 7 compound 7:
Step 1): 2-(5-bromo-2-methylbenzene [1 ', 1 '-D2] benzyl 5-(4-fluorophenyl) [2 ', 3 '-D2] thiophene VII-1
With reference to embodiment 1 step 4) method prepare compound VII-1.
1H-NMR(CDCl3, 300MHz): δ 7.47 (2H, dd, J1=5.4Hz, J2=8.4Hz, Ph), 7.34 (1H, s,
Ph), 7.29 (1H, d, J=8.1Hz, Ph), 6.99-7.04 (3H, m, Ph), 2.26 (3H, s, Me).
13C-NMR (300MHz, DMSO-d6): δ 163.78,160.51,142.05,141.83,140.25,135.27,
132.16,132.03,130.74,130.70,129.90,127.21,127.10,119.65,115.87,115.58,18.97。
Step 2): (3R, 4S, 5S, 6R)-2-3-((5-(4-fluorophenyl) [3 ', 4 '-D2] thiophene-2-base) [D2] methyl)-
4-tolyl)-6-(methylol)-2-methoxyl group tetrahydrochysene-2H-pyrans-3,4,5-triol VII-2
With reference to embodiment 2 step 3) method prepare compound VII-2.
1HNMR (300MHz, DMSO-d6): δ 7.55-7.60 (2H, m, Ph), 7.43 (1H, s, Ph), 7.33 (1H, d, J=
7.0Hz, Ph), 7.13-7.22 (3H, m, Ph), 4.88 (1H, d, J=5.3Hz, OH), 4.63 (1H, d, J=4.9Hz, OH),
4.57 (1H, d, J=7.3Hz, OH), 4.46 (1H, d, J=6.0Hz, OH), 3.73-3.79 (1H, m, sugar), 3.52-3.64
(2H,m,sugar),3.39-3.42(1H,m,sugar),3.19-3.24(1H,m,sugar),2.96(3H,s,OMe),2.90-
2.93(1H,m,sugar),2.26(3H,s,Me);
13C-NMR (300MHz, DMSO-d6): δ 162.92,159.68,143.66,140.04,137.19,136.79,
135.03,130.51,129.32,128.68,126.91,126.81,125.99,123.33,115.92,115.64,100.79,
77.02,74.32,73.77,70.22,60.94,48.15,18.60。
HRMS (ESI) m/z:478.1713.
Step 3): (2S, 3R, 4R, 5S, 6R)-2-3-((5-(4-fluorophenyl) [3 ', 4 ' D2] thiophene-2-base) [D2] first
Base)-4-tolyl)-6-(methylol)-tetrahydrochysene-2H-pyrans-3,4,5-triol 7
With reference to embodiment 1 step 6) method prepare compound 7.
1HNMR (300MHz, DMSO-d6): δ 7.56-7.60 (m, 2H, dd, J1=8.6Hz, J2=5.5Hz, Ph), 7.10-
7.25 (5H, m, Ph), 4.86 (2H, d, J=4.4Hz, OH), 4.66 (1H, d, J=5.0Hz, OH), 4.37 (1H, t, J=
5.7Hz, OH), 3.98 (1H, d, J=9.1Hz, sugar), 3.69-3.74 (1H, m, sugar), 3.45-3.48 (1H, m,
sugar),3.15-3.29(4H,m,sugar),2.26(s,3H)。
13C-NMR (300MHz, DMSO-d6): δ 162.94,159.69,143.39,140.18,138.16,137.21,
134.83,130.47,129.57,128.98,126.94,126.83,126.16,123.22,115.92,115.63,81.26,
81.11,78.46,74.64,70.43,61.43,33.33,18.70。
HRMS (ESI) m/z:448.1618.
The preparation of embodiment 8 compound 6:
(2S, 3R, 4R, 5S, 6R)-2-3-((5-(4-fluorophenyl) thiophene-2-base) [D2] methyl)-4-tolyl)-6-
(methylol)-tetrahydrochysene-2D-pyrans-3,4,5-triol 6
With reference to embodiment 1 step 6) method prepare compound 6.
1HNMR (300MHz, DMSO-d6): δ 7.56~7.61 (2H, dd, J1=8.6Hz, J2=5.5Hz, Ph), 7.10~
7.22 (5H, m, Ph), 4.89~4.90 (2H, d, J=4.4Hz), 4.69~4.71 (1H, d, J=5.6Hz), 4.39~4.43
(1H, t, J=5.7Hz), 3.67~3.72 (1H, m, sugar), 3.40~3.47 (1H, m, sugar), 3.12~3.27 (4H,
M, sugar), 2.25 (s, 3H).
HRMS (ESI) m/z:448.1618.
The preparation of embodiment 9 compound 28
Rapid 1): the bromo-5-of 2-(4-fluorophenyl) [2,3-D2] thiophene phenol IX-1
Weighing type II-1 compound (5.0g, 28.1mmol) in pressure pipe, adds deuterated water 14ml (700mmol), cold
But after 0 DEG C, it is slowly added to P2O5(28.4g, 200mmol), stirs 5min under room temperature, be heated to 120 DEG C and stir 24 hours.Cold
But after 0 DEG C, add water (80ml), use CH2Cl2Extract reactant liquor (3 × 60ml).MgSO4After drying, filtrate is distilled at ambient pressure
Oily residue Formulas I-4 compound (5.0g) is obtained after removing solvent.
1H-NMR(CDCl3, 300MHz): δ 7.71-7.67 (m, 2H), 7.22-7.28 (t, 2H).
HRMS (ESI) m/z:181.0494.
Replace Formula II-1 compound with Formulas I-4 compound, and with reference to embodiment 2 step 1) described in method formula IX-1
Compound.
1H-NMR (CDCl3,300MHz): δ 7.51 (m, 2H), 7.02 (m, 2H).
HRMS (ESI) m/z:257.9481.
Rapid 2): (bromo-2 aminomethyl phenyls of 5-) (5-(4-fluorophenyl) [2,3-D2] thiophene phenol-2-base ketone IX-2
Replace Formula II-2 compound with Formula IX-1 compound, and with reference to embodiment 2 step 1) described in method formula IX-
2 compounds.
1HNMR (300MHz, CDCl3): δ 7.62~7.66 (2H, m), 7.57 (1H, s), 7.49~7.52 (1H, dd, J1
=8.2Hz, J2=1.8Hz), 7.09~7.18 (3H, m), 2.33 (3H, s).
HRMS (ESI) m/z:375.9906.
Rapid 3): (5-bromo-2-aminomethyl phenyl) (5-(-4-fluorophenyl)-[2,3-D2] thiophene) [D]-methyl alcohol IX-3
Formula IX-2 compound (2.65g, 7.06mmol) is joined in 100mL single port flask, is sequentially added into acetonitrile
(25mL)、[D4] sodium borohydride (0.40g, 10.87mmol).Unlatching is heated to reactant liquor backflow, and after 3 hours, TLC shows raw material
Reaction is completely.Reactant liquor joins in 20mL heavy water under stirring after being cooled to room temperature, has more solid to separate out.Mixed liquor subtracts
Pressure suction filtration.Faint yellow solid IX-3 (2.51g) is obtained after filtration cakes torrefaction.
1HNMR (300MHz, CDCl3): δ 7.79 (s, 1H), 7.52-7.47 (m, 2H), 7.33 (d, 1H), 7.06-6.98
(m,3H),6.66(d,1H),2.25(s,3H)。
HRMS (ESI) m/z:379..0123.
Step 4): ((5-bromo-2-aminomethyl phenyl) (5-(-4-fluorophenyl)-[2,3-D2] thiophene) [D] methoxyl group) trimethyl
Silane IX-4
Compound IX-3 (1.5g, 3.95mmol) is joined in 25mL there-necked flask, is sequentially added into oxolane
(15mL), N-methylmorpholine (0.61mL, 5.13mmol).Reaction bulb is transferred in-20 DEG C of low-temp reaction baths, question response liquid temperature
Degree is slowly added to trim,ethylchlorosilane (0.61mL, 4.74mmol) after being down to-20 DEG C.React after continuing stirring under low temperature 5 minutes
Bottle is transferred to be stirred at room temperature, and after three hours, TLC display starting material left is less.30mL petroleum ether, 20mL water are added sequentially to instead
Answering in liquid, be sufficiently stirred for rear separatory, aqueous phase 20mL petroleum ether extracts once again, separatory, merges organic phase, organic phase 15mL
Saturated potassium dihydrogen phosphate washs, and anhydrous sodium sulfate revolves after drying and steams to obtain light yellow viscous liquid.Crude product column chromatography purifies, stone
Oil ether-ethyl acetate (10:1, V/V) system elutions, (1.5g, 3.32mmol receive to obtain light yellow viscous liquid Formula IX-4 compound
Rate 84.1%).
1HNMR (300MHz, CDCl3): δ 7.79 (s, 1H), 7.52-7.47 (m, 2H), 7.32 (d, 1H), 7.06-6.98
(m,2H),2.25,(s,3H),0.14(s,9H)。
HRMS (ESI) m/z:451.0514.
Step 5): (2S, 3R, 4R, 5S, 6R)-2-3-((5-(4-fluorophenyl) [2,3-D2] thiophene-2-base) hydroxyl [D] first
Base)-4-tolyl)-6-(methylol)-2-methoxyl group tetrahydrochysene-2H-pyrans-3,4,5-triol IX-5
Compound IX-4 (1.61g, 3.55mmol) is joined 100mL be dried in there-necked flask, nitrogen displacement reaction bottle
Middle air.Successively dry toluene (10mL), anhydrous tetrahydro furan (15mL) are injected reaction bulb with syringe under nitrogen protection.Will
Reaction bulb is placed in the bath of-78 DEG C of low temperature, and in question response liquid, temperature drop is to after-78 DEG C, by n-butyllithium solution (1.56mL,
3.9mmol, 2.5M) it is slowly injected in reactant liquor, reactant liquor quickly becomes navy blue, and whole dropping process continues 10 minutes, protects
In holding reactant liquor, temperature is less than-65 DEG C.After 30 minutes, by be dissolved in 50mL dry toluene TMS-glucolactone I-8 (1.66g,
During 3.55mmol) solution is slowly injected into reactant liquor, whole dropping process continues 10 minutes, and in keeping reactant liquor, temperature is less than-61 DEG C.
Reactant liquor continues to stir 2 hours in-78 DEG C of low temperature baths.By the absolute methanol (15mL) of pyrovinic acid (1.36g, 14.2mmol)
Solution is slowly injected in reaction bulb, and in keeping reactant liquor, temperature is less than-60 DEG C.Drip complete, reaction bulb is placed under outdoor conditions
Continue stirring reaction 3 hours.Under condition of ice bath, 30mL saturated sodium bicarbonate solution is slowly added in reactant liquor, is sufficiently stirred for
Rear separatory, water layer 20mL ethyl acetate is extracted twice, and merges organic layer, and saturated nacl aqueous solution (3 × 10mL) washs, anhydrous
Sodium sulphate revolves after drying and steams to obtain off-white color solid.Crude product silica gel column chromatography is purified, acetate-methanol wash-out (10:1, V/
V), white solid Formula IX-5 compound (1.12g, yield 63.9%) is obtained.
1HNMR (300MHz, CDCl3): δ 1H-NMR (300MHz, DMSO-d6): δ 7.57~7.65 (3H, m, Ph), 7.36
~7.38 (1H, m, thio), 7.11~7.29 (m, 3H, Ph), 4.93 (1H, d, 5.3Hz, OH), 4.64~4.69 (2H, m,
OH), 4.49~4.51 (1H, m, OH), 3.73~3.76 (1H, m, sugar), 3.54~3.61 (2H, m, sugar), 3.38~
3.43 (1H, m, sugar), 3.20~3.30 (1H, m, sugar), 2.99 (3H, s, OMe), 2.25 (3H, s, Me).
HRMS (ESI) m/z:493.1652.
Step 6): (2S, 3R, 4R, 5S, 6R)-2-3-((5-(4-fluorophenyl) [3 ', 4 '-D2] thiophene-2-base) methyl)-
4-tolyl)-6-(methylol)-tetrahydrochysene-2H-pyrans-3,4,5-triol 28
Addition Formula IX-5 compound (0.5g, 1.03mmol) in 25ml three-necked bottle, triethyl silicane (0.72ml,
4.18mmol), 8ml CHCl2, N2Protection, is down to-70 DEG C.Boron trifluoride ether solution it is slowly added dropwise in reactant mixture
(0.5ml, 3.99mmol).Rise to 0 DEG C of reaction 2h.Saturated NaHCO is added in reactant mixture3Solution 10ml, ethyl acetate
Extraction, the anhydrous MgSO of organic layer4It is dried.Steaming solvent, column chromatography for separation obtains white solid formula 28 compound (0.3g), yield
65%.
1H-NMR (300MHz, DMSO-d6): δ 7.56~7.60 (2H, dd, J1=8.6Hz, J2=5.5Hz, Ph), 7.10
~7.25 (5H, m, Ph), 4.83 (2H, s, OH), 4.65 (1H, s, OH), 4.35 (1H, s, OH), 4.12 (1H, s, Ph-CHD-
Thio), 3.98 (1H, d, J=9.2Hz, sugar), 3.69~3.73 (1H, m, sugar), 3.47 (1H, m, sugar), 3.18
~3.28 (4H, m, sugar), 2.26 (3H, s, Me).
13C-NMR (300MHz, DMSO-d6): δ 162.92,159.68,143.47,140.16,138.15,137.26,
134.83,130.49,129.56,128.98,126.93,126.82,126.15,123.32,115.91,115.62,81.24,
81.10,78.44,74.62,70.41,61.41,33.33(m),18.70。
HRMS (ESI) m/z:447.1593.
Normal SD rats sugar tolerance and glucose in urine are drained by embodiment 9 canagliflozin, compound 1, compound 3 and compound 7
The impact of amount
One) test method
Rat [CD (SD) body weight 160-180 gram] 20, fasting 18h can't help water, is randomly divided into 5 groups by blood sugar and body weight:
Normal group, canagliflozin (1.0mg/kg) group, compound 1 (1.0mg/kg) group, compound 3 (1.0mg/kg) group, chemical combination
Thing 7 (1.0mg/kg) group, gavage gives relative medicine (1.0mg/kg), and normal group gives equal-volume water for injection.After administration
30min, ig give rat glucose 3g/kg, and administration volume is 1.5ml/100g, and Rat Fast terminates to experiment, and tail point is taken a blood sample
Measure before being administered and to 0.5h after GLU, 1,2,4,6,8, the blood sugar of 24h, collect and give after glucose 02,24,4-6,6-10,
10 24h rat urine, (4,6h collect every rat after urine and supplement water, ig 5mL water for injection), measure urine volume and take
After 1ml, 1000r/min*5min are centrifugal, measure glucose in urine.Testing index and computational methods are as follows:
(1) AUC (0~tnBefore)=(administration+be administered after t0)*t0/ 2+ (t after administration0T after+administration1)*(t1-t0)/2+ (gives
T after medicine1T after+administration2)*(t2-t1)/2+......+ (t after administrationn-1T after+administrationn)*(tn-tn-1)/2
(2) blood sugar rate of descent (%)=(normal group-administration group)/normal group × 100%
(3) blood sugar AUC rate of descent (%)=(normal group blood sugar AUC-administration group blood sugar AUC)/normal group blood sugar AUC ×
100%
(4) sugar excretion=glucose in urine * volume of urine
(5) sugar excretion rate=sugar excretion/give sugar measure
Two) data statistics processing method
Data press statistical requirements, represent by mean+SD (x ± s), and all data use Microsoft Excel
Software carries out t inspection, and analysis result.
Three) experimental result
(1) impact on normal rat sugar tolerance
After rats in normal control group gavage gives glucose, 30min blood glucose value significantly raises, and 60min blood sugar reaches the highest,
Declining occurs in 120min blood glucose value.Compare with Normal group, except compound 1 treated animal is under rat blood sugar time graph after sugar
Area AUC (0-24) conspicuousness reduces beyond (p < 0.05), each group rat glucose load 0.5h, 1,2,4,6,8,24h blood sugar with
Different periods blood sugar AUC is without significant difference.To 2h after sugar rat blood sugar rate of descent is respectively as follows: 15% ,-13% ,-8% ,-
4%, rat blood sugar AUC (0-2h) rate of descent is respectively as follows: 5%, 3%, 0%, 0%;To 24h after sugar, rat blood sugar rate of descent is divided
Not being: 15%, 18%, 6%, 13%, rat blood sugar AUC (0-24h) rate of descent is respectively as follows: 13%, 12%, 4%, 7%.Result
It is shown in Table 1-4.
Table 1. on the impact of glucose load rat blood sugar (N=4)
Table 2. on the impact of glucose load rat blood sugar-AUC (N=4)
The impact that glucose load rat blood sugar AUC is declined by table 3.
The impact that glucose load rat blood sugar is declined by table 4.
(2) impact on normal rat urine sugar excretion
Compare with normal group, each group of glucose excretion that all can increase in glucose load rat 24h, descending be followed successively by
Compound 1 (1mg/kg) group ≈ canagliflozin (1mg/kg) group > compound 7 (1mg/kg) group ≈ compound 3 (1mg/kg) group.
Canagliflozin, compound 1, compound 3, compound 7 (1mg/kg) group rat 0 10h glucose in urine excretion rate is respectively as follows: 11.6%,
14.7%, 10.5%, 11.2%, difference is extremely notable (P < 0.01) compared with Normal group;Each group rat 10-24h glucose in urine row
The rate of letting out is respectively as follows: 2.4%, 1.5%, 2.2%, 1.6%.Show arrange sugar be concentrated mainly on 0~10h, 10~24h periods arrange sugar measure
Less.Each experimental group rat is more or less the same in row's sugar amount of 0-2,2-4,4-6,6-10,10-24h, and urine glucose lowering effect is more slow
With, and corresponding to its hypoglycemic activity trend.The results are shown in Table 5-10.
Glucose load rat different time sections urine row's sugar is measured by table 5. to be affected (N=4)
Note: compared with Normal group, * P < 0.05, * * P < 0.01
Table 6. on glucose load rat different time sections urine volume affect (N=4)
Note: compared with Normal group, * P < 0.05, * * P < 0.01.
Table 7. on the impact of glucose load rat different time sections glucose in urine excretion rate (N=4)
Note: compared with Normal group, * P < 0.05, * * P < 0.01.
Table 8. on glucose load rat accumulation urine row sugar amount impact (N=4)
Note: compared with Normal group, * P < 0.05, * * P < 0.01.
Table 9. on glucose load rat accumulation urine volume affect (N=4)
Note: compared with Normal group, * P < 0.05, * * P < 0.01.
Table 10. on the impact of glucose load rat accumulation glucose in urine excretion rate (N=4)
Note: compared with Normal group, * P < 0.05, * * P < 0.01.
Four) brief summary
It is followed successively by normal SD rats hypoglycemic activity is descending: compound 1 (1mg/kg) group ≈ canagliflozin (1mg/
Kg) group > compound 7 (1mg/kg) group ≈ compound 3 (1mg/kg) group.
Descending to the Excretion of glucose in urine it is: compound 1 (1mg/kg) group > canagliflozin (1mg/kg) group >ization
Compound 7 (1mg/kg) group ≈ compound 3 (1mg/kg) group.
Embodiment 10 canagliflozin and compound 1 metabolic stability Journal of Sex Research in people's hepatomicrosome
(1) external temperature incubates operation
1) taking out people's hepatomicrosome 3 to manage (often pipe 50 μ L, 20mg/mL), often pipe liver particle body temperature incubates solution system: 395 μ
LPBS, adds 50 μ L hepatomicrosome solution (5.0mg/mL), 5 μ L substrates, mixes and get final product.
2) weigh about 8.4mg NADPH and add 500 μ L PBS dissolvings, add 500 μ L MgCl2Mixing.
3) divide and take 450 μ L (n=2) temperature and incubate solution constant-temperature table temperature and incubate, incubate 5min in 37 DEG C of pre-temperature.NADPH mixing is molten
Liquid is (containing MgCl2) also to incubate 5min in 37 DEG C of pre-temperature stand-by.
4) drawing 54 μ L temperature and incubate solution in 1.5mL Eppendorf pipe, add 6 μ L pH7.4PBS buffer solutions, vortex mixes
Even, it is 0min sample.
5) residue temperature is incubated in solution every part and is added 44 μ L NADPH mixed solutions (containing MgCl2) start and react (the most organic
The ratio of solvent is 1%), 37 DEG C of temperature are incubated and timing.After arriving the setting time, shift 60 μ L sample to adding 120 μ L reactions
The 1.5mL Eppendorf pipe of stop buffer terminates reaction.
6) vortex mixing 3min, in 4 DEG C, 12000rpm be centrifuged 3min, took for 80 μ L of supernatant nights, add 80 μ L pure water, mixing,
Carry out LC-MS/MS analysis.
7) if any anomaly and operation, timely record.
(2) microsome sample treatment
Draw 60 μ L microsome samples, add the ice acetonitrile precipitation of 200 μ L containing the internal standard, after vortex concussion 5min, centrifugal
(13800rpm, 4 DEG C) 10min.TQ1501-754a, TQ1501-001a, DEX Aspirate supernatant 80 μ L, adds in 96 orifice plates
The acetonitrile of the 1:1 of 80 μ L: water, vortex mixes, and 1 μ L sample introduction is analyzed.
(3) data acquisition and processing (DAP) method
This time test mainly sees compound elimination situation in vitro, using 0 as reference, with the ratio with internal standard peak area
Value compares as data.The most do not do corresponding calibration curve and the Quality Control of each compound.
(4) estimation of pharmacokinetic parameters
Clearance rate computing formula:V/M=1/protein concentration
(5) measured data result
I. the right Mei Shafen of positive control (DEX) result
External 1 μM of DEX temperature incubates 120min, sees table 11 relative to 0min change numerical value.
The external 1 μM of DEX temperature of table 11 is incubated relative 0min and is remained percentage
The most external canagliflozin and compound 1 temperature incubate result
Canagliflozin, compound 1 temperature are incubated 90min, sees table 12 relative to 0min change numerical value.
Table 12 canagliflozin, compound 1 temperature are incubated in 90min, remain percentage relative to 0min
The most external temperature incubates parametric fitting results
Positive drug, canagliflozin, compound 1 parametric fitting results are shown in Table 13.
Table 13 positive drug, canagliflozin, compound 1 parametric fitting results
(6) brief summary
1) half-life of positive drug dextromethorphan is 34.79min, between 30~50min, meets the requirements, prompting experiment
Reliable results.
2) canagliflozin and compound 1 have certain metabolism in people's hepatomicrosome in 90min, but the half-life is equal > 200min,
Prompting metabolism is slowly.
3) compound 1 of same concentrations is more longer than canagliflozin half-life in people's hepatomicrosome system, and stability is more
Good.
Claims (8)
1. the compound shown in a Formulas I or its pharmaceutically acceptable salt:
Wherein R1、R2Independently selected from H, D or OH;R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15Separately select
From H or D, R3Independently selected from C1-C4Alkyl or deuterated C1-C4Alkyl, condition is R1~R15In including at least a D-atom.
2. the compound of claim 1, wherein R3Independently selected from CH3、CH2D、CHD2Or CD3。
3. the compound of claim 1, it is selected from following compound:
4. the compound of claim 1, it is selected from following compound:
5. a pharmaceutical composition, its compound comprising claim 1 or its pharmaceutically acceptable salt, and a kind of or many
Plant pharmaceutically acceptable carrier, excipient and/or medium.
6. the pharmaceutical composition of compound any one of claim 1-4 or its pharmaceutically acceptable salt, claim 5 exists
Purposes in the medicine of the disease that SGLT-2 suppression is benefited from preparation treatment.
7. the purposes of claim 6, the wherein said disease of SGLT-2 suppression of benefiting from is selected from diabetes, diabetic retinal
Disease, diabetic neuropathy, diabetic nephropathy, wound healing delay, insulin resistance, hyperglycemia, hyperinsulinism
The rising of mass formed by blood stasis, aliphatic acid blood concentration, the rising of glycerine blood concentration, hyperlipidemia, obesity, hypertriglyceridemia, X syndrome,
Atherosclerotic or hypertension.
8. the purposes of claim 7, the wherein said disease of SGLT-2 suppression of benefiting from is selected from diabetes.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510079247 | 2015-02-14 | ||
CN2015100792471 | 2015-02-14 | ||
CN201510533263 | 2015-08-26 | ||
CN2015105332633 | 2015-08-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105884755A true CN105884755A (en) | 2016-08-24 |
CN105884755B CN105884755B (en) | 2019-05-28 |
Family
ID=57014793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610077280.5A Active CN105884755B (en) | 2015-02-14 | 2016-02-04 | The carbon glycoside derivative of deuterium modification |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105884755B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107540648A (en) * | 2017-08-09 | 2018-01-05 | 江苏工程职业技术学院 | A kind of preparation method of Dapagliflozin |
CN107573311A (en) * | 2017-08-09 | 2018-01-12 | 江苏工程职业技术学院 | A kind of synthetic method of Dapagliflozin |
CN108530434A (en) * | 2017-03-03 | 2018-09-14 | 重庆医药工业研究院有限责任公司 | Impurity compound of canagliflozin and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1829729A (en) * | 2003-08-01 | 2006-09-06 | 田边制药株式会社 | Novel compounds |
WO2012140120A1 (en) * | 2011-04-13 | 2012-10-18 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of sglt2 |
-
2016
- 2016-02-04 CN CN201610077280.5A patent/CN105884755B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1829729A (en) * | 2003-08-01 | 2006-09-06 | 田边制药株式会社 | Novel compounds |
WO2012140120A1 (en) * | 2011-04-13 | 2012-10-18 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of sglt2 |
Non-Patent Citations (1)
Title |
---|
NICHOLAS A. MEANWELL: ""Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design"", 《JOURNAL OF MEDICINAL CHEMISTRY》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108530434A (en) * | 2017-03-03 | 2018-09-14 | 重庆医药工业研究院有限责任公司 | Impurity compound of canagliflozin and preparation method thereof |
CN107540648A (en) * | 2017-08-09 | 2018-01-05 | 江苏工程职业技术学院 | A kind of preparation method of Dapagliflozin |
CN107573311A (en) * | 2017-08-09 | 2018-01-12 | 江苏工程职业技术学院 | A kind of synthetic method of Dapagliflozin |
Also Published As
Publication number | Publication date |
---|---|
CN105884755B (en) | 2019-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110944997B (en) | FXR receptor agonists | |
TWI284533B (en) | Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant | |
WO2011052756A1 (en) | Novel 3-hydroxy-5-arylisoxazole derivative | |
CN101137660A (en) | Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives as antidiabetic compounds | |
RU2680248C1 (en) | Combination containing new derivative 3-(4-(benzyloxy)phenyl)hex-4-in-acid and other active ingredient to activate g-protein 40 of the receptor enzyme | |
CN105884755B (en) | The carbon glycoside derivative of deuterium modification | |
CN109316601A (en) | Medical composition and its use | |
CN105367565B (en) | Piperazine (pyridine) cyclohexyl derivatives and its application for treating Mental disease | |
CN106748970A (en) | The deoxidization nojirimycin derivative of N aryl 1 and its application in treatment diabetes medicament is prepared | |
CN107488162A (en) | A kind of bicyclic alcohol derivatives and its preparation and application | |
CN107709332B (en) | C, O-spiro aryl glycoside compound and preparation and application thereof | |
WO2014146606A1 (en) | C-triaryl glucoside sglt-2 inhibitors | |
WO2020035058A1 (en) | Pharmaceutical compounds for treating liver diseases and application thereof | |
CN104817554A (en) | Glucoside derivatives and pharmaceutical compositions thereof | |
EP3466940B1 (en) | Crystal form of sodium-glucose cotransporter 2 inhibitor | |
CN106349099B (en) | Caffeic acid-lysine and its derivative, preparation method and purposes | |
JP6576445B2 (en) | Aromatic compounds of farnesyl and their applications | |
KR20090091615A (en) | Tetracera scandens extracts and 4h-chromen-4-one derivatives isolated therefrom increasing glucose uptake in differentiated l6 muscle cells | |
CN107235842B (en) | Phenylpropanoate derivative and preparation method and application thereof | |
CN108623555B (en) | Benzoxel compound, preparation method thereof, pharmaceutical composition and application thereof | |
CN101040934A (en) | Medicine compound made of haw leaf and rhodiola | |
CN102675244A (en) | Thiazine amide derivative and application thereof in preparation of medicines for preventing and controlling neurodegenerative diseases | |
US8431577B2 (en) | Crystalline form of eszopiclone, composition, preparation and uses thereof | |
CN106146488A (en) | The Preparation method and use of 9 substituted double-functional group berberinc derivates | |
CN104788412B (en) | Aromatic polycyclic carboxylic acid derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230921 Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province Patentee after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd. Patentee after: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd. Address before: 222006 No. 8 Julong North Road, Sinpo District, Jiangsu, Lianyungang Patentee before: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd. |